Semaglutide vs Tirzepatide: A Researcher’s Comparison of GLP-1 and Dual-Incretin Agonists

By Justin Cartier

For the wider context, see our overview of research peptides for weight loss.

Here’s the question everyone circles back to: which one drops more weight? Semaglutide and tirzepatide are both injectable peptides studied for blood sugar and weight loss, and honestly, the difference comes down to one thing, and that thing is receptors. Semaglutide hits just one of them, GLP-1, while tirzepatide hits two, GIP and GLP-1. That extra receptor is basically why the trials keep handing tirzepatide the win at the top doses.^[2][4]

This article is for research and educational use only. These are research peptides, not medicines as sold here, and aren’t for human use.

So why does the dual one tend to win? It really is about coverage. Semaglutide just copies the natural hormone GLP-1 and nothing more. Tirzepatide is one molecule flipping on the GIP receptor and the GLP-1 receptor at the same time, and that added GIP signal seems to push weight reduction past whatever GLP-1 pulls off alone. Stick with me and we’ll go through the receptor-level differences, what the trial data actually say about body weight, blood sugar, muscle, and side effects, and what to keep in mind if you’re designing a comparison study.

What is semaglutide?

It’s a long-acting peptide that mimics GLP-1 to lower blood sugar levels and quiet appetite. The design is genuinely clever. It shrugs off the enzyme DPP-4 and grabs onto albumin in the blood, and those two tricks stretch its half-life to roughly a week. Lau’s group, in the Journal of Medicinal Chemistry, spells out the two swapped amino acids, at positions 8 and 34, that buy it all that staying power versus human GLP-1.^[1] Novo Nordisk got it approved for type 2 diabetes back in 2017 as Ozempic, then for weight management in 2021 as Wegovy, dosed at 2.4 mg by injection once a week.

What is tirzepatide?

This is the new kid, and the first dual-receptor incretin peptide to actually reach the market. It hits GIP and GLP-1 at once. Willard’s team, in JCI Insight, calls it a biased, imbalanced agonist, which is a fancy way of saying it leans on the GIP receptor while behaving like a plain GLP-1 copy at the GLP-1 receptor.^[2] Eli Lilly walked it through FDA approval for type 2 diabetes in May 2022 as Mounjaro, then for weight management in November 2023 as Zepbound, with weekly doses climbing step by step from 2.5 mg up to 15 mg.

Key differences between semaglutide and tirzepatide

Receptor count is the headline, but it’s worth unpacking what each receptor buys you. GLP-1 signaling, the part both peptides share, works the brain and pancreas: it makes you feel full, slows the stomach down, releases insulin when glucose runs high, and drags blood sugar lower. GIP is the bonus receptor, and it adds an extra insulin-boosting nudge at the pancreas, and it seems to tweak how fat cells handle lipids and how the brain reads appetite, though nobody’s fully nailed down those details yet. Both carry a type 2 diabetes approval. Both are cleared for weight management in the United States. And for a researcher, that overlap is the whole appeal, because you’ve got the same broad indication and two different receptor strategies, which is about as clean a natural experiment in incretin pharmacology as you’ll find.

Structure splits them too. Semaglutide keeps the 31-residue GLP-1 backbone, just those two changes plus a fatty-acid linker for the albumin trick. Tirzepatide is a bigger 39-residue blend built on a GIP core, even though its action runs mostly GLP-1-driven at the GLP-1 receptor. Don’t think of them as interchangeable copies. They genuinely belong to two different receptor-pharmacology classes.

Weight loss outcomes: which is better for weight loss?

At the doses tested, tirzepatide just takes off more. Look at semaglutide first. In the STEP-1 trial of the 2.4 mg weekly dose, Wilding’s group, in the New England Journal of Medicine, watched adults with overweight or obesity lose roughly 14.9 percent of their starting body weight over 68 weeks, which is a genuinely big number on its own.^[3]

Then the dual agonist showed up and moved the goalposts. SURMOUNT-1 enrolled people with obesity or overweight and no diabetes, and the weight reduction just kept climbing with the dose: about 15 percent at 5 mg, 19.5 percent at 10 mg, and a frankly striking 20.9 percent at 15 mg over 72 weeks. That’s Jastreboff’s team, again in the New England Journal of Medicine.^[4] Head-to-head clinical trials in type 2 diabetes tell the same story, with tirzepatide out front on weight and glycemic numbers both, and the systematic review pile only points one way.

How quickly does weight loss happen?

Both show something inside the first 12 weeks, so you’re not waiting forever. Rosenstock’s group, in the Lancet, tracked dose-dependent loss in an earlier tirzepatide diabetes trial, from around 7 percent at the low doses up toward the bigger figures at 15 mg, and the curve was still dropping through about week 26 before it leveled.^[5] In SURMOUNT-1, the 10 mg group hit roughly 6 percent by week 12 and 14 percent by week 24. Semaglutide under STEP-1? About 6 percent by week 12 and 10 percent by week 24, with visible loss as early as week 8. How fast it goes really does depend on dose, starting weight, and how quickly you escalate. And the early gut side effects keep pace with all of it.

Muscle loss with semaglutide or tirzepatide

Here’s where people worry, and mostly they’re worrying about the wrong thing. Lean-mass loss with either one looks like what happens in any sustained calorie deficit, drug or no drug. DEXA scans across the STEP and SURMOUNT programs put about 25 to 40 percent of total weight lost as fat-free mass when nobody’s lifting weights. There’s no solid published evidence that one strips more muscle than the other beyond what total weight loss already predicts. So if you’re comparing them, match for calorie deficit and resistance-training exposure first. Don’t pin the muscle loss on the molecule.

Side effects and adverse events

The side-effect profiles basically rhyme, and they’re mostly gut: nausea, vomiting, diarrhea, constipation. In the main trials, 4 to 7 percent of people quit over adverse events, tirzepatide running a touch higher at 15 mg. The rare serious stuff has included pancreatitis, gallstones (more likely when the weight comes off fast), and a thyroid C-cell tumor signal that turned up in rodents and hasn’t been confirmed in humans.

Availability in Canada

Semaglutide’s been around in Canada as Ozempic since 2018, with Wegovy arriving in 2024. Tirzepatide showed up in November 2024 as Mounjaro for type 2 diabetes, while the Zepbound weight-management brand still hadn’t launched here as of 2026. Research-only material for both peptides is sold as a research chemical for laboratory use only; our guide to buying peptides in Canada covers how those rules work.

Switching between semaglutide and tirzepatide

Nothing in the prescribing information forbids switching. It’s the practical stuff that bites. The titration schedule restarts from the bottom. That early gut side-effect window swings back open. And the first weeks on the new peptide feel slower than the steady state you just left, which can be discouraging if you’re not expecting it. Running a crossover design? Plan a washout of at least 5 weeks, given the one-week half-life of both and the slow tail off the albumin-bound supply.

Skip the guesswork on quality and buy Canadian research peptides from a supplier that verifies every lot.

Semaglutide vs tirzepatide questions

Which is better for weight loss, semaglutide or tirzepatide?

Across the evidence, tirzepatide gives larger average weight loss at the highest studied doses (about 20.9 percent at 15 mg) than semaglutide (about 14.9 percent at 2.4 mg). Head-to-head diabetes trials put it ahead on both weight and blood sugar. The exact gap depends on dose and starting weight.

How quickly can you expect to lose weight on tirzepatide?

About 6 percent by 12 weeks at the 10 mg dose, around 14 percent by 24 weeks, with the curve flattening near 60 to 72 weeks. Speed depends on dose pace, starting weight, and consistency.

Do you lose more muscle on semaglutide or tirzepatide?

There’s no solid evidence that one costs more muscle than the other beyond what total weight loss predicts. DEXA scans in both programs show 25 to 40 percent of weight lost is fat-free mass without strength training.

Is tirzepatide available in Canada?

Yes. Mounjaro launched in Canada in November 2024 for type 2 diabetes. The Zepbound brand hadn’t launched as of 2026, so prescribers writing for weight management currently use Mounjaro off-label or in a clinical-trial setting.

What are the key differences between semaglutide and tirzepatide?

Semaglutide is a pure GLP-1 receptor copy; tirzepatide turns on both GIP and GLP-1 receptors. Semaglutide carries two changed amino acids versus natural GLP-1; tirzepatide is a 39-residue blended peptide. In comparison studies, tirzepatide gives larger weight loss and a slightly higher gut side-effect rate at the top doses.

Key data point: head-to-head trials in type 2 diabetes show the dual GIP/GLP-1 agonist tirzepatide produces greater weight loss and lower blood sugar than the single-receptor GLP-1 agonist semaglutide at approved doses.^[2][4]

Summary

So, where does that leave you? Semaglutide and tirzepatide are the two most important incretin peptides for obesity and type 2 diabetes, and they split on three things: receptor coverage (single versus dual), how much weight they shed in trials (about 15 percent versus about 21 percent at the top doses), and current Canadian availability. Both drive steady, meaningful weight loss in adults with overweight or obesity. Both share that gut-dominant side-effect pattern. And both make genuinely useful research peptides for studying incretin biology, glycemic control, and weight management. The move is to pick your comparison endpoint first, then match the molecule and dose to the question, not the other way around.

Sources: [1] Discovery of once-weekly semaglutide (GLP-1 analogue), PubMed. [2] Tirzepatide is a dual GIP and GLP-1 receptor agonist, PubMed. [3] Once-weekly semaglutide in adults with overweight or obesity (STEP-1), PubMed. [4] Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), PubMed. [5] Tirzepatide in type 2 diabetes (SURPASS-1), PubMed.

Justin Cartier

The Reviv Peptides Research Team is a collective of science writers and researchers dedicated to producing evidence-based, peer-reviewed-grade content about research peptides. Our work focuses on molecular mechanisms, receptor pharmacology, and preclinical data — including GLP-1/GIP/glucagon incretin biology, growth hormone axis peptides (GHRH analogs and ghrelin-receptor secretagogues), mitochondrial-derived peptides (MOTS-c, SS-31), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), and nootropic peptides (Semax, Selank). All content is written in a strict preclinical/laboratory context; none of our editorial material is intended as medical advice. Every guide is reviewed for scientific accuracy against published peer-reviewed literature.